- In February 2024, the U.S. FDA approved Xolair (omalizumab) for reducing allergic reactions to multiple food allergens, including peanuts, for both children and adults. This breakthrough marks the first FDA-approved medication for managing multiple food allergies by desensitizing the immune response, significantly improving quality of life for allergy sufferers
- In January 2024, Japanese researchers at NARO (National Agriculture and Food Research Organisation) developed a genetically modified rice designed to reduce allergic reactions to cedar pollen, a major cause of hay fever in Japan. This rice contains trace amounts of allergens to build immune tolerance and is undergoing further clinical trials
- In April 2024, a report by Climate Central revealed that climate change is intensifying allergy seasons, causing earlier pollen release and longer exposure periods. Higher CO₂ levels and rising global temperatures are linked to increased allergen production, leading to more severe and widespread allergic reactions globally
- In May 2023, Metropolis Healthcare introduced an AI-powered 4th-generation allergy testing platform using Component Resolved Diagnostics (CRD). The new system enables precise identification of allergen sensitivities across 295 parameters, enhancing personalized treatment plans and diagnostic accuracy in environmental allergies
